Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

By Michael Weller, J. Felsberg, C. Hartmann, H. Berger, J. Steinbach, J. Schramm, M. Westphal, G. Schackert, M. Simon, J. Tonn and 8 more. Journal of Clinical Oncology, 2009

613 citations recorded by the source corpus.

Subfields: Genetics, Neurology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/7e7f27123841fc74eafe01d99fe22ce0feb18028

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller
2. Guido Reifenberger

Citations in the corpus

• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010, methodology): “Clinical and molecular data are derived from 94 patients with anaplastic astrocytoma treated in the NOA-04 trial [25] and from 51 patients with anaplastic astrocytoma and 237 patients with glioblastoma included in the prospective translational cohort study of the GGN [23].”
• MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, background): “prognostic factor for outcome in patients with newly diagnosed glioblastoma, and is a powerful predictor of response to alkylating chemotherapy (Table 2).(10,11,13,38,40,41) The 2”
• Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “In addition to providing insights about the origin of gliomas, the mutational status of IDH1/2 serves as a prognostic marker in patients with WHO grade II and III gliomas [58, 123, 141, 181] and GBMs [172].”